✦ LIBER ✦

123 EFFICACY AND SAFETY OF AN INTENSIFIED REGIMEN OF PEGYLATED INTERFERON ALFA-2A PLUS RIBAVIRIN IN HCV GENOTYPE 1 NON-RESPONDERS: AN INTERIM ANALYSIS OF THE SYREN TRIAL

✍ Scribed by C. Hézode; J. Foucher; J.-P. Bronowicki; V. Leroy; A. Tran; D. Larrey; P. Mathurin; I. Rosa; L. Alric; V. Dhalluin-Venier; A. Nani; M. Bouvier-Alias; S. Rouanet; P. Couzigou; A. Mallat; M. Charaf-Eddine; J.-M. Pawlotsky

Book ID: 117377134
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 51 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(09)60125-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

95 EFFICACY AND SAFETY OF THE CYCLOPHILI

95 EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS

✍ D.R. Nelson; R.H. Ghalib; M. Sulkowski; E. Schiff; V. Rustgi; P.J. Pockros; C. W 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

187 Efficacy and safety of 22 weeks of m

187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYS™) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial

✍ Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmora 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

335 Interim results of a randomized tria

335 Interim results of a randomized trial of 1.5μG/ KG vs. 3.0 μG/KG pegylated interferon alfa 2-B PEG-intron(R) (PEG) plus ribavirin (RBV) for naïve chronic hepatitis C patients and 3.0μG/KG PEG plus RBV for non-responders (NR) and relapsers (R) to previous therapy. (The target trial)

✍ Calvin L. White; Peter F. Malet; Corinne L. Wentworth; Veronica L. Cantu; Tamera 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB